TCGA-56-7730-01A-11R-2125-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 73
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.480
- G2M_CHECKPOINT+0.400
- MYC_TARGETS_V2+0.370
- MYC_TARGETS_V1+0.350
- WNT_BETA_CATENIN_SIGNALING+0.260
- DNA_REPAIR+0.250
- MITOTIC_SPINDLE+0.240
- SPERMATOGENESIS+0.170
- KRAS_SIGNALING_DN+0.100
- MTORC1_SIGNALING+0.100
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.580
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.530
- INTERFERON_GAMMA_RESPONSE-0.500
- IL6_JAK_STAT3_SIGNALING-0.490
- INFLAMMATORY_RESPONSE-0.470
- INTERFERON_ALPHA_RESPONSE-0.450
- ANGIOGENESIS-0.410
- COMPLEMENT-0.410
- COAGULATION-0.350
- TNFA_SIGNALING_VIA_NFKB-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-J1-A4AH-01A-31R-A24H-07 | — | cohortSQ2 | 0.959 |
| 2 | SRR6013540 | — | cohortSQ2 | 0.937 |
| 3 | TCGA-98-A53A-01A-11R-A262-07 | — | cohortSQ1 | 0.936 |
| 4 | TCGA-66-2793-01A-01R-1201-07 | — | cohortMD1 | 0.935 |
| 5 | TCGA-85-8580-01A-31R-2403-07 | — | cohortSQ2 | 0.935 |
| 6 | TCGA-AN-A04D-01A-21R-A034-07 | — | E | 0.932 |
| 7 | BS_S69QZAJR | medulloblastoma | — | 0.932 |
| 8 | dd75267f-824e-4ddc-9056-cdf0f500d39b | — | — | 0.929 |
| 9 | C3L-01285 | — | cohortSQ2 | 0.925 |
| 10 | BS_K3ER45RV | medulloblastoma | — | 0.924 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.480 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.370 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.350 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.260 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.250 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.240 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.170 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.080 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.050 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.030 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.010 | Remibrutinib | — uncovered |